Multiple Myeloma Clinical Trial
— DSM XIIIOfficial title:
The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma
In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m² augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before transplantation and lenalidomide maintenance after transplantation.
Status | Completed |
Enrollment | 348 |
Est. completion date | January 31, 2020 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Understand and voluntarily sign an informed consent form. 2. Age 60-75 years at the time of signing the informed consent form. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Symptomatic MM requiring therapy. 5. Measurable monoclonal protein in serum and/or urine 6. Monoclonal plasma cells in the bone marrow >/= 10% and/or biopsy-proven plasmacytoma 7. Myeloma-related organ dysfunction, at least one of [C] Calcium elevation in the serum (> 11.5 mg/dL or > 2.65 mmol/l) [R] Renal insufficiency (creatinine > 173 µmol/l or > 2 mg/dL) [A] Anemia (Hb < 10 g/dL or 2 g/dL < normal) [B] Bone lesions or general osteoporosis 8. ECOG PS of </= 2 ... 9. Laboratory test results within these ranges within 1 week prior to randomization: - ANC >/= 1.0 x 109/L. - Platelet count >/= 75 x 109/L or in case of bone marrow infiltration with myeloma cells >/= 30 x 109/L. - Total bilirubin </= 2 mg/dL. - AST (SGOT) and ALT (SGPT) </= 3 x ULN. 8. Female subjects of childbearing potential must: o Understand the study drug is expected to have a teratogenic risk o Agree to use, ..., effective contraception without interruption,... o Understand that even if she has amenorrhea, she must follow all the advice on effective contraception. o She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy o Agree to have a medically supervised pregnancy test ... - Male subjects must o Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study drug therapy ... - Agree not to donate semen during study drug therapy and for one week after end of study drug therapy. - All subjects must - Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy. - Agree not to share study drug with another person and to return all unused study drug to the investigator. 9. Disease free of prior malignancies for >/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast. 10. Able to receive antithrombotic prophylaxis (...). 11. Life-expectancy > 3 months. Exclusion Criteria: 1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF. 2. Pregnant or lactating females 3. Any condition, incl. the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 4. Patient currently is enrolled in another clinical research study or has been enrolled ...within 4 weeks before randomization and/or is receiving an investigational agent for any reason ... 5. Known hypersensitivity to thalidomide, dexamethasone, or melphalan. 6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. 7. Any prior use of lenalidomide. 8. Concurrent use of other anti-cancer agents or treatments. 9. Known positive for HIV or active infectious hepatitis, type A, B or C or treponema pallidum 10. Prior treatment with dexamethasone discontinued because of = grade 3 dexamethasone-related toxicity. 11. Any prior chemotherapy with the exception of a short course of dexamethasone more than 4 weeks before randomization. 12. Immunotherapy or antibody therapy within 8 weeks before randomization. 13. Major surgery within 4 weeks before randomization. 14. Renal failure requiring dialysis. 15. Myocardial infarction within 6 months before randomization, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. 16. Severe pulmonary disease (diffusion capacity < 60% of normal). 17. Treatment for cancer other than MM within 5 years before randomization, with the exception of basal cell carcinoma or cervical cancer in situ. 18. Cardiac amyloidosis. 19. Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol. 20. Any systemic infection requiring treatment. 21. Unability or unwillingness of the patient to receive antithrombotic prophylaxis. - |
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsklinikum Aachen | Aachen | |
Germany | Agirov Klinik | Berg | |
Germany | HELIOS Klinikum Berlin-Buch | Berlin | |
Germany | Evangelisches Krankenhaus Bielefeld | Bielefeld | |
Germany | Klinikum Bremen-Mitte | Bremen | |
Germany | Universitätsklinik Erlangen | Erlangen | |
Germany | Universitätsklinikum Freiburg | Freiburg | |
Germany | Universitätsklinikum Göttingen | Göttingen | |
Germany | Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald -Anstalt öffentlichen Rechts- | Greifswald | |
Germany | Asklepios Klinik Altona | Hamburg | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Universitätsklinikum Schleswig-Holstein | Kiel | |
Germany | Stiftungsklinikum Mittelrhein gGmbH | Koblenz | |
Germany | Klinikum Landshut gemeinnützige GmbH | Landshut | |
Germany | Universitätsklinikum Münster | Muenster | North Rhein Westfallen |
Germany | Hämato-Onkologische Schwerpunktpraxis | München | |
Germany | Klinikum München Harlaching | München | |
Germany | Klinikum rechts der Isar | München | |
Germany | Onkologische Praxis Elisenhof | München | |
Germany | Stauferklinikum Schwäbisch Gmünd | Mutlangen | |
Germany | Klinikum Nord | Nürnberg | |
Germany | Klinikum Oldenburg | Oldenburg | |
Germany | Klinikum Ernst von Bergmann gGmbH | Potsdam | |
Germany | Gemeinschaftspraxis für Innere Medizin, Hämatologie und Onkologie | Ravensburg | |
Germany | Klinikum der Universität Regensburg | Regensburg | |
Germany | Diakonie-Klinikum Stuttgart-Diakonissenkrankenhaus und Paulinenhilfe gGmbH | Stuttgart | |
Germany | Robert-Bosch-Krankenhaus | Stuttgart | |
Germany | Klinikum Traunstein | Traunstein | |
Germany | Universitätsklinikum Ulm | Ulm | |
Germany | HSK Dr. Horst-Schmidt-Kliniken gmbh | Wiesbaden | |
Germany | Universitätsklinikum Würzburg | Würzburg |
Lead Sponsor | Collaborator |
---|---|
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | ClinAssess GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | To compare the efficacy of both treatment regimens with regard to progression-free survival. | 5 yrs | |
Secondary | Overall survival (OS) | To assess the safety and overall survival of both treatment regimens. | 5 yrs | |
Secondary | • Response (complete response [CR], stringent complete response [sCR], very good partial response [VGPR], partial response [PR] and overall response [CR (incl. sCR)+ VGPR + PR]) according to IMWG criteria | To investigate other efficacy parameters of both treatment regimens | 5 yrs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |